COMPOUND DEEP DIVES
The AOD-9604 GH fragment is a synthetic peptide derived from the C-terminal region of human growth hormone (GH), specifically encompassing amino acids 176–191 with an added N-terminal tyrosine residue. Unlike full-length GH, this truncated sequence has attracted significant preclinical attention for its apparent ability to modulate lipid metabolism in obese rodent models without triggering the IGF-1-mediated growth effects or glucose dysregulation associated with intact GH. Research suggests that AOD-9604 may represent a structurally elegant tool for dissecting the lipolytic and anti-adipogenic pathways of the GH molecule in a laboratory context.
AOD-9604 (Anti-Obesity Drug 9604) was originally synthesised by researchers at Monash University, notably Ng FM and colleagues, who sought to isolate the fat-metabolising domain of GH from its anabolic and mitogenic activities. The peptide spans residues 176–191 of the GH backbone and incorporates a tyrosine residue at position 1 to stabilise the helical conformation and improve receptor interaction in preclinical assays.
In animal models, research suggests AOD-9604 exerts its lipolytic effects primarily through engagement of the β3-adrenergic receptor (β3-AR) pathway on adipocytes. Activation of this receptor triggers intracellular cyclic AMP (cAMP) cascades that stimulate hormone-sensitive lipase (HSL) activity, resulting in the hydrolysis of stored triglycerides into free fatty acids and glycerol. Importantly, researchers have observed that this mechanism appears to operate independently of IGF-1 receptor signalling, which underpins the growth-promoting and insulin-sensitising effects of full-length GH.
Heffernan M et al. conducted foundational studies demonstrating that obese rodents administered AOD-9604 experienced measurable reductions in adipose depot mass without concurrent changes in lean body mass, IGF-1 plasma concentrations, or glucose tolerance. These findings positioned the peptide as a biochemically distinct lipolytic agent suitable for mechanistic adipose research.
Multiple preclinical investigations have examined how AOD-9604 influences fat cell biology across different adipose compartments. In obese Zucker rat models, researchers have observed dose-dependent reductions in both visceral and subcutaneous adipose tissue following administration over several weeks. These reductions correlated with upregulated expression of uncoupling protein-1 (UCP-1) in brown adipose tissue, suggesting a potential thermogenic component that our team of specialist reviewers has noted warrants further mechanistic characterisation in isolated cell systems.
Beyond triglyceride hydrolysis, preclinical data indicate that AOD-9604 may inhibit adipogenesis — the differentiation of preadipocytes into mature fat cells. Ng FM and collaborators reported that the peptide suppressed peroxisome proliferator-activated receptor gamma (PPARγ) expression in 3T3-L1 cell cultures, a widely used in vitro adipogenesis model. Downregulation of PPARγ is associated with impaired lipid droplet accumulation and reduced expression of downstream adipogenic markers such as FABP4 and adiponectin.
These dual effects — stimulating existing lipid breakdown while attenuating new fat cell formation — have made AOD-9604 a subject of verified interest among metabolic peptide researchers. Specialists studying adipose tissue remodelling frequently reference this compound alongside other metabolic peptides such as MOTS-c, which has been examined for its mitochondrial and metabolic regulatory properties, as part of broader investigations into energy homeostasis pathways.
A key reason AOD-9604 has been authenticated as a preferred research tool in lipolysis studies is its differential activity profile compared to full-length GH and the unmodified Fragment 176–191. The comparison table below summarises parameters researchers have examined across preclinical models:
| Parameter | Full-Length GH | Fragment 176–191 (unmodified) | AOD-9604 (176–191 + Tyr) |
|---|---|---|---|
| Lipolytic activity (rodent models) | Moderate — via HSL and β3-AR | Moderate | Strong — β3-AR preferential |
| IGF-1 stimulation | High | None observed | None observed |
| Anabolic/growth effects | Pronounced in multiple tissues | Not observed in preclinical data | Not observed in preclinical data |
| Adipogenesis inhibition (PPARγ suppression) | Indirect / context-dependent | Partial | Reported in 3T3-L1 models |
| Glucose metabolism impact | Insulin resistance risk at high doses | Minimal reported | Neutral in reviewed preclinical studies |
| Cartilage / chondrocyte activity | Significant — via GH receptor | Limited data | Investigated — see articular research below |
| Half-life / stability | Variable (pulsatile) | Short | Improved with Tyr addition |
This profile has led expert researchers to employ AOD-9604 as a tool for isolating the lipolytic arm of GH signalling without confounding anabolic variables — a methodological advantage that is particularly relevant in obesity and metabolic syndrome research programmes.
Beyond its established role in adipose biology, preclinical investigations have explored AOD-9604 in articular tissue contexts. Research suggests the peptide may influence chondrocyte metabolism and extracellular matrix gene expression independently of its lipolytic activities. Studies in cartilage explant models and isolated chondrocyte cultures have reported modulation of collagen type II and aggrecan expression following AOD-9604 exposure, findings that an authenticated panel of specialist reviewers has noted could have relevance for osteoarthritis disease-model research.
These observations are consistent with the known role of GH-derived signals in skeletal biology and expand the potential research applications of AOD-9604 beyond metabolic science. Researchers interested in broader metabolic and mitochondrial pathways may also find value in reviewing data on MOTS-c’s exercise-mimetic AMPK and mitochondrial signalling properties, which intersect with energy substrate utilisation pathways relevant to adipose research programmes.
Preclinical safety data for AOD-9604 have generally been described as favourable within the reviewed literature. Toxicology studies in rodent and primate models reported no significant adverse effects on organ histology, haematological parameters, or reproductive endpoints at doses used in metabolic research protocols. Heffernan M et al. documented the absence of mitogenic or tumourigenic signals in long-term rodent studies, a finding that expert commentators attribute to the peptide’s lack of IGF-1 receptor engagement.
Our team emphasises that all safety assessments referenced here are derived from controlled preclinical laboratory settings and cannot be extrapolated to any other context. This compound is strictly a research tool for qualified laboratory use.
View AOD-9604 Research Compound
The AOD-9604 GH fragment is a synthetic peptide comprising amino acids 176–191 of human growth hormone, with an added N-terminal tyrosine residue. Unlike full-length GH, it does not stimulate IGF-1 production or produce anabolic/growth effects in preclinical models. Research suggests it selectively engages lipolytic pathways, making it a specialist tool for isolating the fat-metabolising domain of GH biology in laboratory research.
Preclinical data indicate that AOD-9604 preferentially activates the β3-adrenergic receptor (β3-AR) on adipocytes. This triggers a cAMP-mediated signalling cascade that stimulates hormone-sensitive lipase (HSL), promoting hydrolysis of stored triglycerides. Researchers have observed this mechanism appears to function independently of the GH receptor and IGF-1 signalling arms that drive growth and insulin modulation.
Yes. Beyond lipolytic activity, preclinical research has investigated AOD-9604 in the context of adipogenesis inhibition — specifically PPARγ suppression in 3T3-L1 cell models — as well as in articular tissue studies examining chondrocyte gene expression. These findings extend the potential research utility of the compound into cartilage biology and metabolic disease modelling.
Reviewed preclinical toxicology studies, including work by Heffernan M et al., reported no significant adverse organ, haematological, or reproductive findings in rodent and primate models at research-relevant doses. The absence of IGF-1 stimulation and mitogenic signalling was specifically noted. All safety data are derived from controlled laboratory research and apply solely to that context.
AOD-9604 was developed by researchers at Monash University, with Ng FM among key contributors. The rationale was to synthesise a peptide that retained the lipolytic properties of the GH C-terminal domain while eliminating the growth-promoting and insulin-resistance-associated effects of the intact GH molecule. This structural isolation strategy has since become a template for fragment-based peptide research in metabolic biology.
The addition of the N-terminal tyrosine residue in AOD-9604 is reported to improve peptide stability and receptor interaction relative to the unmodified Fragment 176–191 sequence. Comparative preclinical assessments suggest AOD-9604 exhibits stronger and more consistent lipolytic activity in obese rodent models, which is why it has become the more widely referenced form in metabolic peptide research literature.
No. AOD-9604 is strictly a laboratory research compound. All data cited in this article derive from in vitro cell studies and preclinical animal models. This compound is not approved for human use, not intended for personal administration, and not available for sale to the general public. It is available exclusively for qualified scientific research purposes.
Disclaimer: This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.